APOE and BDNF as genetic risk markers for predicting the onset and development of cognitive deficits due to Alzheimer's disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F20%3A00073449" target="_blank" >RIV/00159816:_____/20:00073449 - isvavai.cz</a>

Result on the web

<a href="https://www.csnn.eu/en/journals/czech-and-slovak-neurology-and-neurosurgery/2020-3-3/apoe-and-bdnf-as-genetic-risk-markers-for-predicting-the-onset-and-development-of-cognitive-deficits-due-to-alzheimer-s-disease-122980/download?hl=cs" target="_blank" >https://www.csnn.eu/en/journals/czech-and-slovak-neurology-and-neurosurgery/2020-3-3/apoe-and-bdnf-as-genetic-risk-markers-for-predicting-the-onset-and-development-of-cognitive-deficits-due-to-alzheimer-s-disease-122980/download?hl=cs</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14735/amcsnn2020257" target="_blank" >10.14735/amcsnn2020257</a>

Result language

čeština

Original language name

APOE and BDNF as genetic risk markers for predicting the onset and development of cognitive deficits due to Alzheimer's disease

Original language description

Alzheimer&apos;s disease (AD) is a progressive neurodegenerative disorder that is typically initialized by neuronal death in the hippocampus and mediotemporal structures with characteristic episodic memory impairment. However, what is different among AD patients is the age of onset and progression of the disease. It has been suggested that the major modulators of these factors appear to be genetic polymorphisms in apolipoprotein E (APOE) and brain-derived neurotrophic factor (BDNF) genes. APOE 4 allele is the primary genetic determinant of risk for late-onset AD. BDNF Val66Met polymorphism has been shown to alter the risk for developing cognitive impairment and disease progression, both directly and indirectly through an interaction with the APOE genotype. The carriage of both risky variants APOE 4/BDNF Met was associated with episodic memory impairment and faster memory decline compared to the presence of only one or none of these high-risk polymorphisms. This information may be useful for improving the early-detection capability of individuals at risk of developing AD, as well as advancing our understanding of polymorphic combinations that predict the rate of disease progression. Some interventional studies also indicate potential for non-pharmacological interventions in disease prevention in high-risk individuals.

Czech name

APOE and BDNF as genetic risk markers for predicting the onset and development of cognitive deficits due to Alzheimer's disease

Czech description

Alzheimer&apos;s disease (AD) is a progressive neurodegenerative disorder that is typically initialized by neuronal death in the hippocampus and mediotemporal structures with characteristic episodic memory impairment. However, what is different among AD patients is the age of onset and progression of the disease. It has been suggested that the major modulators of these factors appear to be genetic polymorphisms in apolipoprotein E (APOE) and brain-derived neurotrophic factor (BDNF) genes. APOE 4 allele is the primary genetic determinant of risk for late-onset AD. BDNF Val66Met polymorphism has been shown to alter the risk for developing cognitive impairment and disease progression, both directly and indirectly through an interaction with the APOE genotype. The carriage of both risky variants APOE 4/BDNF Met was associated with episodic memory impairment and faster memory decline compared to the presence of only one or none of these high-risk polymorphisms. This information may be useful for improving the early-detection capability of individuals at risk of developing AD, as well as advancing our understanding of polymorphic combinations that predict the rate of disease progression. Some interventional studies also indicate potential for non-pharmacological interventions in disease prevention in high-risk individuals.

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

<a href="/en/project/LQ1605" target="_blank" >LQ1605: Translational Medicine</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Česká a slovenská neurologie a neurochirurgie

ISSN

1210-7859

e-ISSN

—

Volume of the periodical

83

Issue of the periodical within the volume

3

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

6

Pages from-to

257-262

UT code for WoS article

000571508700007

EID of the result in the Scopus database

—